Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 1/2 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 33Gastrointestinal 33Breast 13Gynecologic 11Head & Neck 9Other hematologic neoplasm 6Lymphoid 6Other solid neoplasm 5Tumor-Agnostic 4CNS 4Sarcoma 3Genitourinary 2Dermatologic 1

Conditions

Advanced Solid Tumors 2Select Advanced Solid Tumors 1Mesothelioma, Malignant 1Advanced Solid Tumor 1

Interventions

pembrolizumab 35Injections 28Pemetrexed 15Interviews as Topic 15tislelizumab 13Cisplatin 13Carboplatin 13Specimen Handling 12Bevacizumab 11atezolizumab 10Nivolumab 10Practice Guidelines as Topic 9Educational Status 9Standard of Care 8Oxaliplatin 8Methods 8Fluorouracil 8Early Intervention, Educational 8Docetaxel 7Cyclophosphamide 7Cetuximab 7Capecitabine 7toripalimab 6sotorasib 6Paclitaxel 6Leucovorin 6olaparib 5fludarabine 5Platinum 5Ipilimumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Drug Therapy × Other solid neoplasm × 90 days × Clear all
NCT06596473 2026-05-26

A Study of BG-C477 in Participants With Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
310 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05981703 2026-05-22

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
217 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03710876 2026-04-21

INFINITE

Ferring Ventures Limited

Phase 3 Completed
53 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT06832982 2026-04-09

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

Shanghai Pushi Medical Science Co. Ltd

Phase 1 Recruiting
66 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Immunocore Ltd

Phase 1/2 Active not recruiting
410 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡